TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Cynata Therapeutics Limited ( (AU:CYP) ) is now available.
Cynata Therapeutics Limited has announced the application for quotation of 11,500,000 ordinary fully paid securities on the ASX, as part of an At-the-Market Subscription Deed. This move is expected to enhance the company’s financial flexibility and support its ongoing research and development efforts, potentially strengthening its position in the biotechnology sector.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited operates in the biotechnology industry, focusing on the development of stem cell therapies. The company is known for its innovative approach to regenerative medicine, aiming to address unmet medical needs through its proprietary Cymerus™ technology.
Average Trading Volume: 191,275
Technical Sentiment Signal: Sell
Current Market Cap: A$42.93M
For detailed information about CYP stock, go to TipRanks’ Stock Analysis page.